Cargando…

Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza

INTRODUCTION: Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bermejo-Martin, Jesus F, Ortiz de Lejarazu, Raul, Pumarola, Tomas, Rello, Jordi, Almansa, Raquel, Ramírez, Paula, Martin-Loeches, Ignacio, Varillas, David, Gallegos, Maria C, Serón, Carlos, Micheloud, Dariela, Gomez, Jose Manuel, Tenorio-Abreu, Alberto, Ramos, María J, Molina, M Lourdes, Huidobro, Samantha, Sanchez, Elia, Gordón, Mónica, Fernández, Victoria, del Castillo, Alberto, Marcos, Ma Ángeles, Villanueva, Beatriz, López, Carlos Javier, Rodríguez-Domínguez, Mario, Galan, Juan-Carlos, Cantón, Rafael, Lietor, Aurora, Rojo, Silvia, Eiros, Jose M, Hinojosa, Carmen, Gonzalez, Isabel, Torner, Nuria, Banner, David, Leon, Alberto, Cuesta, Pablo, Rowe, Thomas, Kelvin, David J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811892/
https://www.ncbi.nlm.nih.gov/pubmed/20003352
http://dx.doi.org/10.1186/cc8208
_version_ 1782176804842242048
author Bermejo-Martin, Jesus F
Ortiz de Lejarazu, Raul
Pumarola, Tomas
Rello, Jordi
Almansa, Raquel
Ramírez, Paula
Martin-Loeches, Ignacio
Varillas, David
Gallegos, Maria C
Serón, Carlos
Micheloud, Dariela
Gomez, Jose Manuel
Tenorio-Abreu, Alberto
Ramos, María J
Molina, M Lourdes
Huidobro, Samantha
Sanchez, Elia
Gordón, Mónica
Fernández, Victoria
del Castillo, Alberto
Marcos, Ma Ángeles
Villanueva, Beatriz
López, Carlos Javier
Rodríguez-Domínguez, Mario
Galan, Juan-Carlos
Cantón, Rafael
Lietor, Aurora
Rojo, Silvia
Eiros, Jose M
Hinojosa, Carmen
Gonzalez, Isabel
Torner, Nuria
Banner, David
Leon, Alberto
Cuesta, Pablo
Rowe, Thomas
Kelvin, David J
author_facet Bermejo-Martin, Jesus F
Ortiz de Lejarazu, Raul
Pumarola, Tomas
Rello, Jordi
Almansa, Raquel
Ramírez, Paula
Martin-Loeches, Ignacio
Varillas, David
Gallegos, Maria C
Serón, Carlos
Micheloud, Dariela
Gomez, Jose Manuel
Tenorio-Abreu, Alberto
Ramos, María J
Molina, M Lourdes
Huidobro, Samantha
Sanchez, Elia
Gordón, Mónica
Fernández, Victoria
del Castillo, Alberto
Marcos, Ma Ángeles
Villanueva, Beatriz
López, Carlos Javier
Rodríguez-Domínguez, Mario
Galan, Juan-Carlos
Cantón, Rafael
Lietor, Aurora
Rojo, Silvia
Eiros, Jose M
Hinojosa, Carmen
Gonzalez, Isabel
Torner, Nuria
Banner, David
Leon, Alberto
Cuesta, Pablo
Rowe, Thomas
Kelvin, David J
author_sort Bermejo-Martin, Jesus F
collection PubMed
description INTRODUCTION: Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with nvH1N1. METHODS: We profiled 29 cytokines and chemokines and evaluated the haemagglutination inhibition activity as quantitative and qualitative measurements of host immune responses in serum obtained during the first five days after symptoms onset, in two cohorts of nvH1N1 infected patients. Severe patients required hospitalization (n = 20), due to respiratory insufficiency (10 of them were admitted to the intensive care unit), while mild patients had exclusively flu-like symptoms (n = 15). A group of healthy donors was included as control (n = 15). Differences in levels of mediators between groups were assessed by using the non parametric U-Mann Whitney test. Association between variables was determined by calculating the Spearman correlation coefficient. Viral load was performed in serum by using real-time PCR targeting the neuraminidase gene. RESULTS: Increased levels of innate-immunity mediators (IP-10, MCP-1, MIP-1β), and the absence of anti-nvH1N1 antibodies, characterized the early response to nvH1N1 infection in both hospitalized and mild patients. High systemic levels of type-II interferon (IFN-γ) and also of a group of mediators involved in the development of T-helper 17 (IL-8, IL-9, IL-17, IL-6) and T-helper 1 (TNF-α, IL-15, IL-12p70) responses were exclusively found in hospitalized patients. IL-15, IL-12p70, IL-6 constituted a hallmark of critical illness in our study. A significant inverse association was found between IL-6, IL-8 and PaO2 in critical patients. CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases. The exact role of Th1 and Th17 mediators in the evolution of nvH1N1 mild and severe disease merits further investigation as to the detrimental or beneficial role these cytokines play in severe illness.
format Text
id pubmed-2811892
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28118922010-01-28 Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza Bermejo-Martin, Jesus F Ortiz de Lejarazu, Raul Pumarola, Tomas Rello, Jordi Almansa, Raquel Ramírez, Paula Martin-Loeches, Ignacio Varillas, David Gallegos, Maria C Serón, Carlos Micheloud, Dariela Gomez, Jose Manuel Tenorio-Abreu, Alberto Ramos, María J Molina, M Lourdes Huidobro, Samantha Sanchez, Elia Gordón, Mónica Fernández, Victoria del Castillo, Alberto Marcos, Ma Ángeles Villanueva, Beatriz López, Carlos Javier Rodríguez-Domínguez, Mario Galan, Juan-Carlos Cantón, Rafael Lietor, Aurora Rojo, Silvia Eiros, Jose M Hinojosa, Carmen Gonzalez, Isabel Torner, Nuria Banner, David Leon, Alberto Cuesta, Pablo Rowe, Thomas Kelvin, David J Crit Care Research INTRODUCTION: Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with nvH1N1. METHODS: We profiled 29 cytokines and chemokines and evaluated the haemagglutination inhibition activity as quantitative and qualitative measurements of host immune responses in serum obtained during the first five days after symptoms onset, in two cohorts of nvH1N1 infected patients. Severe patients required hospitalization (n = 20), due to respiratory insufficiency (10 of them were admitted to the intensive care unit), while mild patients had exclusively flu-like symptoms (n = 15). A group of healthy donors was included as control (n = 15). Differences in levels of mediators between groups were assessed by using the non parametric U-Mann Whitney test. Association between variables was determined by calculating the Spearman correlation coefficient. Viral load was performed in serum by using real-time PCR targeting the neuraminidase gene. RESULTS: Increased levels of innate-immunity mediators (IP-10, MCP-1, MIP-1β), and the absence of anti-nvH1N1 antibodies, characterized the early response to nvH1N1 infection in both hospitalized and mild patients. High systemic levels of type-II interferon (IFN-γ) and also of a group of mediators involved in the development of T-helper 17 (IL-8, IL-9, IL-17, IL-6) and T-helper 1 (TNF-α, IL-15, IL-12p70) responses were exclusively found in hospitalized patients. IL-15, IL-12p70, IL-6 constituted a hallmark of critical illness in our study. A significant inverse association was found between IL-6, IL-8 and PaO2 in critical patients. CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases. The exact role of Th1 and Th17 mediators in the evolution of nvH1N1 mild and severe disease merits further investigation as to the detrimental or beneficial role these cytokines play in severe illness. BioMed Central 2009 2009-12-11 /pmc/articles/PMC2811892/ /pubmed/20003352 http://dx.doi.org/10.1186/cc8208 Text en Copyright ©2009 Bermejo-Martin et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bermejo-Martin, Jesus F
Ortiz de Lejarazu, Raul
Pumarola, Tomas
Rello, Jordi
Almansa, Raquel
Ramírez, Paula
Martin-Loeches, Ignacio
Varillas, David
Gallegos, Maria C
Serón, Carlos
Micheloud, Dariela
Gomez, Jose Manuel
Tenorio-Abreu, Alberto
Ramos, María J
Molina, M Lourdes
Huidobro, Samantha
Sanchez, Elia
Gordón, Mónica
Fernández, Victoria
del Castillo, Alberto
Marcos, Ma Ángeles
Villanueva, Beatriz
López, Carlos Javier
Rodríguez-Domínguez, Mario
Galan, Juan-Carlos
Cantón, Rafael
Lietor, Aurora
Rojo, Silvia
Eiros, Jose M
Hinojosa, Carmen
Gonzalez, Isabel
Torner, Nuria
Banner, David
Leon, Alberto
Cuesta, Pablo
Rowe, Thomas
Kelvin, David J
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
title Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
title_full Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
title_fullStr Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
title_full_unstemmed Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
title_short Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
title_sort th1 and th17 hypercytokinemia as early host response signature in severe pandemic influenza
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811892/
https://www.ncbi.nlm.nih.gov/pubmed/20003352
http://dx.doi.org/10.1186/cc8208
work_keys_str_mv AT bermejomartinjesusf th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT ortizdelejarazuraul th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT pumarolatomas th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT rellojordi th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT almansaraquel th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT ramirezpaula th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT martinloechesignacio th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT varillasdavid th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT gallegosmariac th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT seroncarlos th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT michelouddariela th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT gomezjosemanuel th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT tenorioabreualberto th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT ramosmariaj th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT molinamlourdes th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT huidobrosamantha th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT sanchezelia th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT gordonmonica th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT fernandezvictoria th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT delcastilloalberto th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT marcosmaangeles th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT villanuevabeatriz th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT lopezcarlosjavier th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT rodriguezdominguezmario th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT galanjuancarlos th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT cantonrafael th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT lietoraurora th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT rojosilvia th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT eirosjosem th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT hinojosacarmen th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT gonzalezisabel th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT tornernuria th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT bannerdavid th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT leonalberto th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT cuestapablo th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT rowethomas th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza
AT kelvindavidj th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza